Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von ADHS und anderen Entwicklungsstörungen

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

  • 1438 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung der ADHS im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Asherson P (2017) Drug treatment for ADHD reduce risk of substance use disorder. Am J Psychiatry 174(9):827–828

    Article  PubMed  Google Scholar 

  • Ashock AH, Mizuno Y, Volkow ND et al (2017) Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine. A systematic review and meta-analysis. JAMA Psychiatry 74(5):511–519

    Article  Google Scholar 

  • Baas S, Lahdo M, Ziemann M, Vaterrodt T (2022) Canabinoide in der Behandlung von ADHS bei Erwachsenen. Neuro Aktuell 7:37–44

    Google Scholar 

  • Banaschewski T, Becker K, Döpfner M et al (2017) Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. Eine aktuelle Bestandsaufnahme. Dt Ärztebl 114(9):149–159

    Google Scholar 

  • Banaschewski T, Hohmann S, Millenet S et al (2018) Langfassung der interdiziplinären evidenz- und konsensbasierten (S3) Leitlinie „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter“. AWMF-Registernummer 028-045

    Google Scholar 

  • Brown JT, Bishop JR, Sangkuhl K et al (2019) Clinical pharmacogenetics implementation consortium guideline for Cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther 106(1):94–102

    Article  PubMed  Google Scholar 

  • Buoli M, Serati M, Cahn W (2016) Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother 16(2):131–144

    Article  CAS  PubMed  Google Scholar 

  • Chang Z, Quinn PD, Hur K et al (2017) Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 74(6):597–603

    Article  PubMed  PubMed Central  Google Scholar 

  • Conzelmann A, Müller S, Jans T et al (2019) Long-term cardiovascular safety of psychostimulants in children with attention deficit hyperactivity disorder. Int J Psychiatry Clin Pract 23(2):157–159

    Article  CAS  PubMed  Google Scholar 

  • Cooper WO, Habel LA, Sox CM et al (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365:1896–1904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cortese S, Moreira-Maia CR, StFleur D et al (2016) Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 173(1):34–43

    Article  PubMed  Google Scholar 

  • Cortese S, Adamo N, Del Giovane C et al (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727–738

    Article  PubMed  PubMed Central  Google Scholar 

  • Dalsgaard S, Kvist AP, Leckman JF et al (2014) Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 24(6):302–310

    Article  PubMed  PubMed Central  Google Scholar 

  • Döpfner M, Banaschewski T (2022) Klassifikation von Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen in der ICD-11. Z Kinder Jugendpsychiatr Psychother 50(1):51–53

    Article  Google Scholar 

  • Faraone SV, Larsson H (2019) Genetics of attention deficit hyperactivity disorder. Rev Mol Psychiatry 24(4):562–575

    Article  CAS  Google Scholar 

  • FDA (2018a) FDA drug safety communication: safety review update of medications used to treat attention-deficit/hyperactivity disorder (ADHD) in adults. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0 (content current as of: 02/13/2018). Zugegriffen: 28. März 2023

  • FDA (2018b) FDA drug safety communication: safety review update of medications used to treat attention-deficit/hyperactivity disorder (ADHD) in children and young adults. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention (content current as of: 02/09/2018). Zugegriffen: 28. März 2023

  • Fekete S, Hiemke C, Gerlach M (2020) Dose-related concentrations of neuro-/psychoactive drugs expected in blood of children and adolescents. Ther Drug Monit 42(2):315–324

    Article  CAS  PubMed  Google Scholar 

  • Habel LA, Cooper WO, Sox CM et al (2011) ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306(24):2673–2683

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hennissen L, Bakker MJ, Banaschewski T (2017) Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. Cns Drugs 31(3):199–215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hirota T, King BH (2023) Autism spectrum disorder: a review. JAMA 329(2):157–168

    Article  CAS  PubMed  Google Scholar 

  • Jensen CM, Amdisen BL, Jørgensen KJ, Arnfred SM (2016) Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. Atten Defic Hyperact Disord 8:3–11

    Article  PubMed  Google Scholar 

  • Ji N, Findling RL (2015) An update of pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry 28(2):91–101

    Article  PubMed  Google Scholar 

  • Katzman MA, Bilkey TS, Chokka PR et al (2017) Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry 17(1):302–317

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim JH, Park S, Lee YL (2023) Systematic review of suicidal behaviors related to methylphenidate and atomoxetine in patients with attention deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 34(2):125-132

    Google Scholar 

  • Kratochvil C (2012) ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk. Am J Psychiatry 169(2):112–114

    Article  PubMed  Google Scholar 

  • Krinzinger H, Hall CL, Groom MJ et al (2019) Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neurosci Biobehav Rev 107:945–968

    Article  CAS  PubMed  Google Scholar 

  • Lam AP, Matthies S, Graf E et al (2019) Long-term effects of multimodal treatment on adult attention-deficit/hyperactivity disorder symptoms. Follow-up analysis of the COMPAS Trial. JAMA Netw Open 2(5):e194980

    Article  PubMed  PubMed Central  Google Scholar 

  • Li L, Chang Z, Sun J, Garcia-Argibay M et al (2022) Attention-deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population-based cohort study. World Psychiatry 21(3):452–459

    Article  PubMed  PubMed Central  Google Scholar 

  • London EB, Yoo JH, Fethke ED et al (2020) The safety and effectiveness of high-dose propranolol as a treatment for challenging behaviors in individuals with autism spectrum disorders. J Clin Psychopharmacol 40(2):122–129

    Article  PubMed  Google Scholar 

  • Lopez PL, Torrente FM, Ciapponi A et al (2018) Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 3(3):CD10840

    PubMed  Google Scholar 

  • Lu Y, Sjölander A, Cederlöf M et al (2017) Association between medication use and performance on higher education entrance tests in individuals with attention-deficit/hyperactivity disorder. JAMA Psychiatry 74(8):815–822

    Article  PubMed  PubMed Central  Google Scholar 

  • Matthijssen AM, Dietrich A, Bierens M et al (2019) Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomized placebo-controlled discontinuation study. Am J Psychiatry 176(9):754–762t

    Article  PubMed  Google Scholar 

  • Moffitt TE, Houts R, Asherson P et al (2015) Is adult ADHD a childhood neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry 172(10):967–977

    Article  PubMed  PubMed Central  Google Scholar 

  • Nazarova VA, Sokolov AV, Chubarev VN et al (2022) Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol 13:1066988

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Poissant H, Mendrek A, Talbot N et al (2019) Behavioral and cognitive impacts of mindfulness-based interventions on adults with attention-deficit hyperactivity disorder: a systematic review. Behav Neuro 2019:5682050

    Google Scholar 

  • Robinson CL, Parker K, Kataria S et al (2022) Viloxazine for the treatment of attention deficit hyperactivity disorder. Health Psychol Res 10(3):38360

    Article  PubMed  PubMed Central  Google Scholar 

  • Sikich L, Kolevzon A, King BH et al (2021) Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med 385(16):1462–1473

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ustun B, Adler LA, Rudin C et al (2017) The world health organization adult attention-deficit/Hyperactivtiy disorder self-report screening scale for DSM-5. JAMA Psychiatry 74(5):520–526

    Article  PubMed  PubMed Central  Google Scholar 

  • Waltereit R, Müller WE (2018) Weiterbildungs-Curriculum Psychopharmakologie/Pharmakotherapie. Teil 4: Psychopharmakologie und klinische Psychopharmakotherapie der Stimulanzien. Psychopharamkotherapie 25(4):199–207

    Google Scholar 

  • Xue J, Zhang Y, Huang Y (2019) A meta-analytic investigation of the impact of mindfulness-based interventions on ADHD symptoms. Medicine 98(23):e15957

    Article  PubMed  PubMed Central  Google Scholar 

  • Young Z, Moghaddam N, Tickle A (2016) The efficacy of cognitive behavioral therapy for adults with ADHD: a systematic review and meta-analysis of randomized controlled trials. J Atten Disord 24(6):875–888

    Article  PubMed  Google Scholar 

  • Yu S, Shen S, Tao M (2023) Guanfacine for the treatment of attention-deficit hyperactivity disorder: an updated systematic review and meta-analysis. J Child Adolesc Psychopharmacol 33(2):40–50

    Article  CAS  PubMed  Google Scholar 

  • Zhou Z, Betts KA, Bocharova I et al (2020) Concomitant use of psychotropic medication with stimulants for the treatment of ADHD in children and adolescents: a retrospective insurance claims study in the United States. J Atten Disord 24(2):336–347

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nordhausen/Freiburg, Deutschland

    Prof. Dr. med. Philip Heiser

  2. Mainz, Deutschland

    Prof. Dr. med. Otto Benkert

Authors
  1. Prof. Dr. med. Philip Heiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Deutschland

    Otto Benkert

  2. ehemals Universitäts-Klinikum München, München, Deutschland

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Heiser, P., Benkert, O. (2023). Medikamente zur Behandlung von ADHS und anderen Entwicklungsstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-67685-1_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-67684-4

  • Online ISBN: 978-3-662-67685-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation